Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.36 |
| ▸ | MPL | P40238 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012999 | 0.89 | RARB (0.41) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL20023225 | 0.87 | RARB (0.40) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL20023226 | 0.87 | RARB (0.40) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL9494063 | 0.85 | LPL (0.42) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL9563689 | 0.83 | MCL1 (0.41) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL20111243 | 0.83 | CNR1 (0.40) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL20117903 | 0.82 | MPL (0.36) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL1249361 | 0.81 | RARB (0.40) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL16377233 | 0.81 | RARB (0.45) | RARBNPC1TP53PKMRAB9A | |
| SCHEMBL9226851 | 0.80 | PTGS2 (0.44) | RARBNPC1TP53PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | RARB 1858/4885NPC1 1740/4885TP53 3011/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | RARB 1858/4885NPC1 1740/4885TP53 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.